Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The objective of this study is to evaluate the mechanism behind the anti-atherogenic effects of liraglutide. In a randomized, placebo-controlled, double-blind, parallel trial we will included 100 patients with type 2 diabetes. Patients will be randomized 1:1 to an active treatment period of 26 weeks or placebo for 26 weeks. The primary endpoint is change from baseline to week 26 in vascular inflammation, assessed by Flour Deoxy Glucose (FDG)-Positron Emission Tomography/Computed Tomography (PET/CT)
Epistemonikos ID: 4ae7c605f214afe94fdff0e302b7d2ec80e3e10e
First added on: Mar 25, 2024